A vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Agilent Technologies exhibits strong fundamental health with a Piotroski F-Score of 8/9, indicating robust accounting strength, and solid profitability metrics including an ROE of 20.62% and operating margin of 26.38%. The company is growing revenue and earnings at double-digit rates, supported by consistent earnings beat rates and strong cash flow generation, though key financial data like Altman Z-Score and cash/debt figures are missing. However, the stock trades at a premium valuation (P/E of 30.28 vs sector average of 215 but with much lower growth than peers), and insider selling activity raises caution. While analysts are bullish with a $169.67 target price, the technical trend is bearish and recent price performance has been weak over the past year despite a short-term rebound.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
A vs JNJ: Head-to-Head Comparison
This page compares Agilent Technologies, Inc. (A) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.